icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TABRECTA (capmatinib).
Voir aussi
Décision d'accès précoce
05/08/2022
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
Es5kvFcYWb4whsWB